Nextleaf Solutions receives a CBD extraction patent from the Canadian intellectual property office

Nextleaf said its cannabinoid (CBD) extraction intellectual property presents an entry point for pharmaceutical firms looking to manufacture CBD prodrugs

Nextleaf Solutions says it now owns the second-largest patent portfolio among all cannabis companies

Nextleaf Solutions Ltd (CSE:OILS) (OTCMKTS:OILFF) reported that it has been granted a patent for the acetylation of cannabinoids (CBD), as well as the subsequent refinement of CBD-O-Acetate using a proprietary extraction and distillation technique, from the Canadian intellectual property office.

Nextleaf noted that it now owns 12 US patents and 70 patents globally for the extraction, purification, and delivery of cannabinoids, which is says represents the second-largest patent portfolio among all cannabis companies.

“We expect the results of the 2020 US elections will have a transformational effect on the commercial value of our US patent portfolio,” Nextleaf Solutions CEO Paul Pedersen said in a statement.  

READ: Nextleaf Solutions takes aim at infused beverages and edibles with patented cannabis extraction technology

He added: “The world's largest cannabis company launching the industry's first patent infringement lawsuit against GW Pharma on December 22, 2020, demonstrates the value of patents and intellectual property in the cannabis industry.”

Nextleaf said it believes an orally-consumable CBD metabolic prodrug produced under its patented process for acetylating cannabidiol will enhance the therapeutic potency of CBD, as it enables the standardization of a more potent analog of CBD through targeted drug delivery.

It added that prodrugs utilize various physical and chemical modifications to improve features of active drugs, as it maintains the integrity of the molecule and its ability to deliver drugs to precisely-targeted areas in the body, which may increase efficacy for desired outcomes.

Nextleaf noted that it already owns US patents for the acetylation of THC, and the acetylation of CBD and suggested that its patent portfolio and Health Canada licenses for cannabis processing and research presents an entry point for pharmaceutical firms looking to manufacture cannabinoid prodrugs in a federally legal jurisdiction.

The company, meanwhile, said it plans to commercialize this intellectual property (IP) through IP licensing, and the production of IP protected cannabinoid-based products as legally permitted by Health Canada.

Nextleaf added that it has engaged Kronos Capital Partners Inc, a strategic advisor and an active investor in the global cannabis and life science sectors, to pursue and evaluate global strategic partners and investors.

Nextleaf Solutions is a cannabis-extraction-technology company that has a patented process for the commercial-scale production of high-quality cannabinoid distillate, the precursor to all cannabis-infused products. 

Contact Sean at sean@proactiveinvestors.com


Price: 0.28 CAD

Market: CSE
Market Cap: $33.74 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of NEXTLEAF SOLUTIONS Ltd. named herein, including the promotion by the Company of NEXTLEAF SOLUTIONS Ltd. in any Content on the Site, the Company...


Nextleaf Solutions signs supply agreement with Bevcanna, a Cannabis infused...

Nextleaf Solutions (CSE: OILS- OTCQB: OILFF) CEO Paul Pedersen joined Steve Darling from Proactive to share details the company’s Rapid Emulsion Technology by OILS will be used to provide THC and CBD concentrate for BevCanna to use in both their brands and their partner brands. Pedersen...

4 days, 13 hours ago

2 min read